Masimo Co. (NASDAQ:MASI) Given Consensus Rating of "Moderate Buy" by Analysts

Masimo Co. (NASDAQ:MASI - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $191.60.

MASI has been the topic of several recent research reports. Wells Fargo & Company reduced their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Raymond James reduced their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Piper Sandler reaffirmed an "overweight" rating and issued a $200.00 price target (down from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Finally, BTIG Research set a $193.00 price target on Masimo and gave the company a "buy" rating in a report on Wednesday, May 7th.

Insider Activity

In related news, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at $4,048,568.28. This trade represents a 55.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,053 shares of company stock worth $6,998,565 over the last three months. 9.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Masimo

Several institutional investors have recently modified their holdings of MASI. Jones Financial Companies Lllp purchased a new stake in shares of Masimo during the fourth quarter valued at $27,000. Twin Tree Management LP purchased a new position in Masimo in the first quarter worth about $29,000. Blue Trust Inc. grew its stake in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 116 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 64 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Trading Down 0.5%

Shares of Masimo stock traded down $0.87 during midday trading on Friday, reaching $162.96. 439,871 shares of the company's stock traded hands, compared to its average volume of 646,671. The company has a market cap of $8.84 billion, a PE ratio of 112.39 and a beta of 1.23. The stock has a 50 day moving average of $157.00 and a 200-day moving average of $167.21. Masimo has a 12 month low of $101.61 and a 12 month high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.12. The company had revenue of $372.00 million for the quarter, compared to analysts' expectations of $367.79 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm's revenue for the quarter was down 24.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.77 earnings per share. As a group, equities analysts expect that Masimo will post 4.1 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.